By Fineline Cube 
China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its HY0001a, an in-house developed CDCP1-directed antibody drug conjugate (ADC).
Drug Target
HY0001a is a Category 1 therapeutic biologic product designed for testing in advanced solid tumors. CDCP1 is highly expressed in various cancers such as gastric, breast, lung, colorectal, and pancreatic cancer, but shows low or no expression in normal tissues, making it a promising target for anti-tumor drugs.
Preclinical Studies
Preclinical studies have demonstrated that HY0001a exhibits excellent anti-tumor effects and good safety across multiple solid tumor models.
Global Status
Currently, no similar product has been approved globally, positioning HY0001a as a potentially groundbreaking treatment option in oncology.-Fineline Info & Tech